EnCare Biotech, focused on the development of novel therapies to prevent heart failure (HF), announced that it has been awarded a Eurostars™ grant together with its consortium partners.The Dutch company was founded by Dr Arslan as a spin-off of the University Medical Center (UMC) Utrecht and will lead an international consortium which includes French diagnostics company Firalis SA and UK-based antibody production company Fusion Antibodies Ltd.
The grant, which totals a budget of almost 1,1 million euro, will be used for the development of antibodies to treat diastolic HF and for the development of companion diagnostics to this therapy.
Diastolic heart failure: It is estimated that of all heart failure patients, approximately 50% suffer from diastolic HF. Currently, no effective treatment is at hand for this type of HF, also referred to as HF with preserved ejection fraction (HFpEF).
Dr Arslan, Founder and CSO at EnCare Biotech B.V. : “Over the last years we have made great progress in establishing the positive effect of the therapeutic antibodies we have developed on wound healing after acute myocardial infarction. This grant will allow us to study the potential beneficial effect of these antibodies in other diseases for which there is a high medical need.”
Encare participated in the Venture Challenge Spring 2010.